You are here: Industry Insights > Psoriasis

News List

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients PharmaSources
October 10, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-488 met the primary endpoint in adult patients with moderate-to-severe plaque psoriasis.
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China PharmaSources
July 05, 2023
On July 5, 2023,InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.
Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis prnasia
January 29, 2022
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray...
Specialist-Led Model of Care Can Improve CVD Prevention in Psoriasis drugs.com
January 19, 2022
Dermatologists and patients with psoriatic disease have a positive view of a specialist-led model of care to improve cardiovascular...
CBD and Cannabis Products for Acne, Psoriasis? Buyer Beware, Dermatologists Say drugs.com
January 17, 2022
Growing numbers of folks are turning to CBD or cannabis products to treat skin conditions like acne or rosacea, but researchers warn that the science on their safety and power hasn't kept up with demand.
FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level Drugs
December 27, 2021
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis Drugs
December 27, 2021
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration’s (FDA)...
Psoriasis Ups Risk for Vascular Disease, Venous Thromboembolism Drugs
December 08, 2021
There is an increased risk for venous thromboembolism (VTE) and peripheral vascular disease (PVD) among patients with psoriatic disease, according to a review published online Dec. 1 in JAMA Dermatology.
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Plaque Psoriasis Accepted by FDA and Validated by European Medicines Agency AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for ...